Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly & CompanyfiledCriticalEli Lilly & Company
Priority to HU9903183ApriorityCriticalpatent/HUP9903183A3/hu
Publication of HUP9903183A2publicationCriticalpatent/HUP9903183A2/hu
Publication of HUP9903183A3publicationCriticalpatent/HUP9903183A3/hu
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
A találmány tárgyát az őlanzapin[2-metil-4-(4-metil-piperazinil)-10H-tienő[2,3-b]benződiazepin] alkalmazása képezi fájdalőmcsillapítóhatású gyógyszerkészítmények előállítására. A találmány szerinti készítmények alkalmasak az akűt, nőiciceptívvalamint az idegrendszer megbetegedésével kapcsőlatős fájdalőmkezelésére. ŕ
HU9903183A1997-03-241997-03-24Use of olanzapine for the preparation of pharmaceutical compositions with analgetic activity
HUP9903183A3
(en)
Composto utilização de um composto composição farmacéutica e processos para o tratamento de um paciente que sofre de dor e para a preparação de um composto
Stable extended release oral dosage composition comprising a pseudoephedrine-containing core, the core being uniformly covered with a desloratadine-containing film
Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
Use of dapiprazole for the manufacture of a pharmaceutical composition inhibiting the development of tolerance in the analgesic treatment with morphine